Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Concord Medical (TASE:BLWV) Services Holdings Ltd (NYSE:CCM), a healthcare provider specializing in cancer care, has filed its annual report for the year ending December 31, 2024, today. The company’s stock has shown recent momentum, gaining over 10% in the past week, though it remains down more than 40% over the past six months. The report was submitted to The Stock Exchange of Hong Kong Limited (HKSE) where Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical, is listed under the stock code 2453.HK.
The filing comes after the company’s previous announcement of the listing of Concord Healthcare’s H shares on the HKSE on January 9, 2024. Concord Medical’s move to file the report is in compliance with the rules governing foreign private issuers as stipulated by the United States Securities and Exchange Commission. According to InvestingPro data, the company faces operational challenges with negative gross profit margins and weak overall financial health scores.
Investors and interested parties can access the details of Concord Healthcare’s annual report through the HKSE’s website. The report provides a comprehensive overview of the company’s financial performance and operational highlights for the past year.
Concord Medical, headquartered in Beijing, operates a network of radiotherapy and diagnostic imaging centers across China. The company’s focus on oncology services positions it within a critical segment of the healthcare industry in the region.
Chairman and Chief Executive Officer Jianyu Yang, who signed off on the SEC filing, leads Concord Medical. The document’s submission reaffirms the company’s commitment to transparency and adherence to international reporting standards.
The information disclosed in this article is based on the company’s latest SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.